CureTB program evaluated continuity of care for tuberculosis patients relocating internationally

This program evaluation describes the CureTB initiative, which aimed to provide continuity of care for patients with tuberculosis who were relocating to other countries. The evaluation covered program activities from 2016 to 2023, but the sample size of patients served was not reported. No comparator group or specific clinical outcomes were defined for assessment.

The evaluation focused on program performance metrics, though specific results, effect sizes, absolute numbers, or statistical measures were not provided. The direction of any effects and the magnitude of program impact remain unreported in this descriptive account.

Safety and tolerability data were not reported, as this was not a clinical trial assessing adverse events. The evaluation did not document limitations of the program or methodological constraints of the assessment itself.

As a program description rather than an effectiveness study, this report illustrates one approach to managing care transitions for tuberculosis patients across borders. Without outcome data or comparisons to standard care, its clinical relevance for practice decisions remains uncertain. The evaluation primarily serves as an implementation case study rather than evidence for clinical decision-making.